Topical Capsaicin for the Management of Painful Diabetic Neuropathy: A Narrative Systematic Review

References

• Tesfaye S , BoultonAJM , DyckPJet al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care33(10), 2285–2293 (2010).
   PubMed Web of Science ®Google Scholar
• Dewanjee S , DasS , DasAKet al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur. J. Pharmacol.833, 472–523 (2018).
   PubMed Web of Science ®Google Scholar
• Vinik AI , NevoretM-L , CaselliniC , ParsonH. Diabetic neuropathy. Endocrinol. Metab. Clin. North Am.42(4), 747–787 (2013).
   PubMed Web of Science ®Google Scholar
• Russell JW , ZillioxLA. Diabetic neuropathies. Continuum20(5 Peripheral Nervous System Disorders), 1226–1240 (2014).
   PubMedGoogle Scholar
• Umanath K , LewisJB. Update on diabetic nephropathy: Core Curriculum 2018. Am. J. Kidney Dis.71(6), 884–895 (2018).
   PubMed Web of Science ®Google Scholar
• Spallone V . Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab. J.43(1), 3–30 (2019).
   PubMed Web of Science ®Google Scholar
• Samsu N . Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed. Res. Int.2021, 1–17 (2021).
   PubMed Web of Science ®Google Scholar
• Tziomalos K , AthyrosVG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev. Diabet. Stud.12(1–2), 110–118 (2015).
   PubMedGoogle Scholar
• Callaghan BC , ChengHT , StablesCL , SmithAL , FeldmanEL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol.11(6), 521–534 (2012).
   PubMed Web of Science ®Google Scholar
• Iqbal Z , AzmiS , YadavRet al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin. Ther.40(6), 828–849 (2018).
   PubMed Web of Science ®Google Scholar
• Vileikyte L , LeventhalH , GonzalezJSet al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care28, 2378–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Qureshi Z , AliMN , KhalidM. An Insight into potential pharmacotherapeutic agents for painful diabetic neuropathy. J. Diabetes. Res.27, 1–19 (2022).
   Google Scholar
• Khdour MR . Treatment of diabetic peripheral neuropathy: a review. J. Pharm. Pharmacol.72(7), 863–872 (2020).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ , LuY , DetkeMJ , LeeTC , IyengarS. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain116(1–2), 109–118 (2005).
   PubMed Web of Science ®Google Scholar
• Hicks CW , SelvinE. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr. Diab. Rep.19(10), 86 (2019).
   PubMed Web of Science ®Google Scholar
• Feldman EL , CallaghanBC , Pop-BusuiRet al. Diabetic neuropathy. Nat. Rev. Dis. Primers.5(1), 41 (2019).
   PubMed Web of Science ®Google Scholar
• Ardeleanu V , TomaA , PafiliKet al. Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina56(1), (2020).
   PubMedGoogle Scholar
• Jingxuan L , LitianM , JianfangF. Different drugs for the treatment of painful diabetic peripheral neuropathy: a meta-analysis. Front. Neurol.12, (2021).
   PubMed Web of Science ®Google Scholar
• van Nooten F , TreurM , PantiriK , StokerM , CharokopouM. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin. Ther.39(4), 787–803.e18 (2017).
   PubMed Web of Science ®Google Scholar
• Moher D , ShamseerL , ClarkeMet al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev.4(1), 1 (2015).
   PubMed Web of Science ®Google Scholar
• Guyatt G , OxmanAD , SultanSet al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J. Clin. Epidemiol.66(2), 151–157 (2013).
   PubMed Web of Science ®Google Scholar
• Hussain N , SaidASA , JavaidFAet al. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients. J. Diabetes Metab. Disord.20(1), 271–278 (2021).
   PubMed Web of Science ®Google Scholar
• Martini C , YassenA , OlofsenE , PassierP , StokerM , DahanA. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups. J. Pain Res.5, 51–59 (2012).
   PubMedGoogle Scholar
• Vinik AI , PerrotS , VinikEJet al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol.16(1), 251 (2016).
   PubMed Web of Science ®Google Scholar
• Simpson DM , Robinson-PappJ , VanJet al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J. Pain18(1), 42–53 (2017).
   PubMed Web of Science ®Google Scholar
• Agoons BB , DehayemYefou M , KatteJCet al. Effect of topical capsaicin on painful sensory peripheral neuropathy in patients with Type 2 diabetes: a double-blind placebo-controlled randomised clinical trial. Cureus12(10), e11147 (2020).
   PubMed Web of Science ®Google Scholar
• Kiani J , AhmadNasrollahi S , Esna-AshariF , FallahP , SajediF. Amitriptyline 2% cream vs. capsaicin 0.75% cream in the treatment of painful diabetic neuropathy (double blind, randomized clinical trial of efficacy and safety). Iran J. Pharm. Res.14(4), 1263–1268 (2015).
   PubMed Web of Science ®Google Scholar
• Kiani J , SajediF , NasrollahiSA , Esna-AshariF. A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. J. Res. Med. Sci.20(4), 359–363 (2015).
   PubMed Web of Science ®Google Scholar
• Kulkantrakorn K , LorsuwansiriC , MeesawatsomP. 0.025% capsaicin gel for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial. Pain Pract.13(6), 497–503 (2013).
   PubMed Web of Science ®Google Scholar
• Biesbroeck R , BrilV , HollanderPet al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv. Ther.12(2), 111–120 (1995).
   PubMed Web of Science ®Google Scholar
• Tandan R , LewisGA , KrusinskiPB , BadgerGB , FriesTJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care15(1), 8–14 (1992).
   PubMed Web of Science ®Google Scholar